Hims & Hers Faces FTC Lawsuit: Implications for Telehealth Investors
Hims & Hers faces regulatory scrutiny, prompting a closer look at its telehealth business model and market sentiment.
BioMarin's Strategic Acquisition: What It Means for Investors
BioMarin's $275M acquisition of Alesta Therapeutics could enhance its rare disease focus and shareholder value.
Curaleaf's Hostile Bid for Aurora Cannabis: Implications for North American Cannabis Investors
Curaleaf's $4/share bid for Aurora Cannabis signals major changes in the cannabis sector, impacting investors across the US and Canada.
Amylyx Pharmaceuticals' Avexitide Phase 3 Success: What Investors Need to Know
Amylyx's Phase 3 success with avexitide shows promise for investors, especially amid past setbacks.
Analyzing the Fulcrum and Slate Merger: A New Era for Migraine Therapies
Fulcrum Therapeutics and Slate Medicines merge to create a powerhouse in migraine therapies, signaling a pivotal shift in the CNS market.
Iovance Biotherapeutics' Q2 Earnings: Strong Momentum in Oncology
Iovance Biotherapeutics showcases promising developments in oncology, highlighted by a key FDA designation and strong clinical response rate…
Moderna's mRNA Flu Vaccine Approval: A Game Changer for Investors
Moderna's FDA approval of the first mRNA flu vaccine could redefine its market potential and growth trajectory.
Bristol Myers Squibb's FDA Approval: Is the Market Overreacting?
Bristol Myers Squibb's recent FDA approval raises questions about investor sentiment and stock valuation.
BridgeBio Pharma Stock Gains 29%: Analyzing Wall Street's Confidence
BridgeBio Pharma's stock has surged 29% in three months, reflecting strong earnings and bullish analyst support.
Lantheus Holdings' Tauklarify Approval: A Game Changer for Alzheimer's Imaging
Lantheus Holdings receives FDA approval for Tauklarify, enhancing its position in the Alzheimer's diagnostics market.
Capricor Therapeutics' Stock Soars 77%: What It Means for Investors
Capricor Therapeutics shares surged 77% after FDA agreed to review DMD drug data, signaling a turnaround for the biotech.
Capricor Therapeutics: A High-Stakes Bet on FDA Decision
Capricor Therapeutics' stock surged 67% after-hours amidst anticipation of an FDA decision on deramiocel.